<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03190603</url>
  </required_header>
  <id_info>
    <org_study_id>Hong Ki Min</org_study_id>
    <nct_id>NCT03190603</nct_id>
  </id_info>
  <brief_title>Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis</brief_title>
  <official_title>Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis Results From MRI Finding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Armed Forces Capital Hospital, Republic of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Armed Forces Capital Hospital, Republic of Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Axial Spondyloarthritis (SpA) is a kind of inflammatory arthritis which includes ankylosing
      spondylitis. Common symptoms of axial SpA are inflammatory back pain, morning stiffness,
      peripheral arthritis, enthesitis. Controlling aforementioned symptoms are one of the goal in
      treatment, and another goal is preventing bony ankylosis of axial skeleton such as spine.
      Ankylosis can limit range of motion and lower the quality of life.

      Non-steroidal antiinflammatory drug (NSAID) and Tumor necrosis factor (TNF)-a inhibitor are
      the current treatment options for axial SpA. These medications can improve pain and stiffness
      of axial SpA patients, however preventing bony ankylosis is not proven. Current study showed
      attenuating inflammation at early stage could prevent further bony destruction and ankylosis
      in axial SpA. Present study is designed to discover the therapeutic effect of NSAID whether
      NSAID could recover the early inflammatory bony change (bone marrow edema at MRI) and prevent
      further bony change.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 20, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spondyloarthritis Research Consortium of Canada (SPARCC) MRI score of sacroiliac joint</measure>
    <time_frame>Baseline, 6 weeks after, 12 weeks after</time_frame>
    <description>Change from baseline SPARCC MRI score of sacroiliac joint at 6 weeks and 12 weeks</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Spondylarthropathies</condition>
  <condition>Magnetic Resonance Imaging</condition>
  <arm_group>
    <arm_group_label>Celecoxib arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Axial Spondyloarthritis patients who takes celecoxib 400mg for day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Continue celecoxib 400mg/day for 3months in axial spondyloarthritis patients.</description>
    <arm_group_label>Celecoxib arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 2009 Assessment of SpondyloArthritis international Society (ASAS) classification
             criteria for axial spondyloarthritis

          2. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) &gt; 4

          3. definite bone marrow edema on Sacroiliac joint MRI

        Exclusion Criteria:

          1. Patients who have underling cancer / infectious disease / kidney disease / liver
             disease / cardiovascular or cerebrovascular disease

          2. Patients who is using TNF-a inhibitor

          3. Patients with side effects of NSAID

          4. Patients with history of peptic ulcer

          5. Patients who can't keep NSAID treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hong Ki Min, M.D.</last_name>
    <phone>82-10-9977-5455</phone>
    <email>alsghdrl1921@naver.com</email>
  </overall_contact>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2017</study_first_submitted>
  <study_first_submitted_qc>June 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2017</study_first_posted>
  <last_update_submitted>June 15, 2017</last_update_submitted>
  <last_update_submitted_qc>June 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Armed Forces Capital Hospital, Republic of Korea</investigator_affiliation>
    <investigator_full_name>Hong Ki Min</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
    <mesh_term>Spondylarthropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

